Brokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $65.00
by Scott Moore · The Cerbat GemShares of Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) have received an average recommendation of “Reduce” from the seven analysts that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $65.00.
A number of brokerages have weighed in on QNCX. Maxim Group lowered Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. cut Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Quince Therapeutics in a report on Monday, December 29th. Wall Street Zen lowered Quince Therapeutics to a “strong sell” rating in a report on Saturday, April 18th. Finally, D. Boral Capital cut Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th.
View Our Latest Research Report on Quince Therapeutics
Quince Therapeutics Price Performance
NASDAQ QNCX opened at $1.36 on Wednesday. The stock has a market capitalization of $22.17 million, a P/E ratio of -0.08 and a beta of 1.33. Quince Therapeutics has a 52-week low of $0.80 and a 52-week high of $45.50. The firm has a 50-day moving average price of $1.21 and a 200 day moving average price of $16.11.
Hedge Funds Weigh In On Quince Therapeutics
A number of large investors have recently made changes to their positions in QNCX. XTX Topco Ltd acquired a new stake in shares of Quince Therapeutics in the second quarter valued at about $37,000. Intellectus Partners LLC acquired a new position in Quince Therapeutics during the fourth quarter worth about $179,000. Hudson Bay Capital Management LP acquired a new position in Quince Therapeutics during the fourth quarter worth about $213,000. Quadrature Capital Ltd purchased a new position in Quince Therapeutics in the fourth quarter valued at about $268,000. Finally, GSA Capital Partners LLP increased its holdings in Quince Therapeutics by 158.0% in the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after buying an additional 53,417 shares in the last quarter. Hedge funds and other institutional investors own 30.75% of the company’s stock.
Quince Therapeutics Company Profile
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.